ALCIDION GROUP LIMITED (ALC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALC

ALC - ALCIDION GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.35
Index:

Alcidion Group provides clinical information technology to support clinicians in decision making, ensuring quality of care for patients. The company operates in Australia and the UK. It listed on the ASX in 2011.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.11

22 May
2026

0.000

OPEN

$0.11

0.000

HIGH

$0.11

40,725

LOW

$0.11

TARGET
$0.16 45.5% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . BMT . DOC . EBO . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
ALC: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 0.1 0.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A - 16.7% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 110.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx40.8 M
Book Value Per Share xxxxxxxxxxxxxxx6.5
Net Operating Cash Flow xxxxxxxxxxxxxxx5.8 M
Net Profit Margin xxxxxxxxxxxxxxx4.06 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx1.89 %
Return on Invested Capital xxxxxxxxxxxxxxx1.87 %
Return on Assets xxxxxxxxxxxxxxx1.44 %
Return on Equity xxxxxxxxxxxxxxx1.89 %
Return on Total Capital xxxxxxxxxxxxxxx-0.63 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx5.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx68 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx18 M
Price To Book Value xxxxxxxxxxxxxxx1.53

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.31 %
Cost of Goods Sold xxxxxxxxxxxxxxx36 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

19/05/2026

1

Buy

$0.16

45.45%

Funded through its balance sheet, Alcidion Group is acquiring Kyra Flow for $3m in cash with a $1m earn out from a unit of Telstra Health, which is expected to be earnings accretive, Bell Potter highlights.

Kyra Health is expected to generate revenue of $3.7m in FY27 with over 90% recurring and earnings (EBITDA) of $1.1m. The company has 33 Australian customers, the analyst notes, across hospitals of which 31 are not pre-existing Alcidion customers.

Buy rating and 16c target are retained. Net profit after tax forecasts are largely unchanged.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.10 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

25/05/2026

1

Buy

$0.14

27.27%

Canaccord Genuity maintains a Buy rating for Alcidion Group with a $0.14 target price following the acquisition of the Kyra Flow product suite from Telstra Health ((TLS)).

The transaction involves an upfront cash consideration of -$3.0m alongside a -$1.0m earn-out component payable 12 months post-completion.

Management expects the acquired asset to generate $3.7m in revenue and $1.1m in underlying earnings in FY26, bringing 31 new customers into the business ecosystem.

Earnings projections across FY27-FY28 are lifted by 14% to 15% to reflect the integration of the highly recurring revenue stream.

The broker views the strategic purchase as an attractively priced and complementary bolt-on capable of driving future cross-selling opportunities across the broader platform.
Access Extra Coverage Research History >

ALC STOCK CHART

FNArena News on ALC

1
Australian Broker Call *Extra* Edition – May 25, 2026

May 25 2026 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Apr 27, 2026

Apr 27 2026 - Daily Market Reports
3
Rudi’s View: Top Picks & Conviction Buys

Mar 19 2026 - Rudi's View
4
In Brief: Avecho, Alcidion, Great Divide Mining

Mar 13 2026 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Mar 12, 2026

Mar 12 2026 - Daily Market Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps